Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10931)
  2. Meeting Abstract (9499)
  3. Review (556)
  4. Book Section (417)
  5. Editorial (336)
  6. Guidelines (158)
  7. Correspondence (118)
  8. Conference Paper (107)
  9. Research Letter (61)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22241)
  2. GSK Faculty (5929)
  3. Genitourinary Oncology Service (5650)
  4. Survivorship Research (5226)
  5. Gastrointestinal Oncology Service (4692)
  6. Breast Medicine Service (4155)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (872)
  6. Leonard Saltz (792)

More People

Years
  1. 2025 (641)
  2. 2024 (1388)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5288)
  2. Annals of Oncology (1297)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (776)
  5. Journal of Thoracic Oncology (532)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5580)
  2. Elsevier Inc. (2662)
  3. American Association for Cancer Research (2327)
  4. Oxford University Press (1819)
  5. Nature Publishing Group (1043)
  6. Springer (981)

More Publishers

Results (22264)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial
    Meeting Abstract

    Jhaveri, K. L.; Hurvitz, S. A.; Brufsky, A.; Bose, R.; de Miguel, M. J.; Evron, E.; Unni, N.; Reid, S. A.; Quinn, D. I.; Mahalingam, D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study
    Meeting Abstract

    Pant, S.; Fan, J.; Oh, D. Y.; Choi, H. J.; Kim, J. W.; Chang, H. M.; Bao, L.; Sun, H. C.; Macarulla, T.; Xie, F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer
    Meeting Abstract

    Saura, C.; Sanz, L.; Kim, J.; Jhaveri, K. L.; Guerrero, A.; Ortega, P. T.; Schott, A. F.; Curigliano, G.; Perez, C. A.; Nanda, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation
    Meeting Abstract

    Goetz, M. P.; Wander, S. A.; Bachelot, T.; Batist, G.; Cortes, J.; Cristofanilli, M.; Curigliano, G.; De Nonneville, A.; Gal-Yam, E. N.; Jhaveri, K. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma
    Meeting Abstract

    Pal, S. K.; Tannir, N. M.; Grell, P.; Gao, X.; Kotecha, R. R.; Picus, J.; De Braud, F. G.; Takahashi, S.; Wong, A.; Suarez, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial
    Meeting Abstract

    Grünwald, V.; Motzer, R. J.; Keizman, D.; Bedke, J.; Schmidinger, M.; Staehler, M. D.; Matveev, V. B.; George, S.; Hutson, T. E.; Vaishampayan, U. N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER)
    Meeting Abstract

    Strickler, J. H.; Cercek, A.; Siena, S.; Andre, T.; Ng, K.; Van Cutsem, E.; Wu, C.; Paulson, A. S.; Hubbard, J. M.; Coveler, A. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy of erdafitinib in adults with advanced solid tumors and non-prespecified fibroblast growth factor receptor mutations in the phase 2 RAGNAR trial: Exploratory cohort
    Meeting Abstract

    Lugowska, I. A.; Schuler, M. H.; Loriot, Y.; Carranza, O.; Iyer, G.; Doi, T.; Qin, S.; Tabernero, J.; Reardon, D. A.; Massard, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649
    Meeting Abstract

    Elimova, E.; Shitara, K.; Moehler, M. H.; Ajani, J. A.; Shen, L.; Garrido, M.; Gallardo, C.; Wyrwicz, L. S.; Yamaguchi, K.; Cleary, J. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK plus non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Jayakrishnan, R.; Nassar, A.; Shepherd, F. A.; Lin, J. J.; Lin, S. H.; Shakya, P.; Dilling, T. J.; Bar, J.; Grohe, C.; Gupta, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save